Venetoclax with azacitidine for treating acute myeloid leukaemia following allogeneic stem cell transplantation

Venetoclax in combination with azacitidine is currently in clinical development for the treatment of acute myeloid leukaemia (AML) following allogeneic stem cell transplantation in children and adults. AML is a rare form of blood cancer that affects the white blood cells resulting in frequent infections for patients. AML also affects red blood cells resulting in other symptoms such as bleeding and breathlessness. AML is an acute cancer which means it progresses quickly and aggressively, needing immediate treatment. Over half of AML patients are not eligible for intensive chemotherapy due to age or other factors that may make the treatments too dangerous, leaving them with limited treatment options.